Results 21 to 30 of about 166,329 (303)
The potential role and application of PARP inhibitors in cancer treatment [PDF]
, 2009 Background: Since many anti-cancer agents act by inflicting DNA damage on tumour cells, there is increasing interest in the use of inhibitors of DNA repair to increase the cytotoxicity of these agents.
Chalmers, Anthony J
core +2 more sources
New Insights for nicotinamide: Metabolic disease, autophagy, and mTOR
Frontiers in Bioscience-Landmark, 2020 Metabolic disorders, such as diabetes mellitus (DM), are increasingly becoming significant risk factors for the health of the global population and consume substantial portions of the gross domestic product of all nations. Although conventional therapies
Kenneth Maiese
doaj +1 more source
PARP inhibition: a promising therapeutic target in ovarian cancer [PDF]
, 2015 Ovarian cancer is burdened by the highest mortality rate among gynecological cancers. Gold standard is represented by the association of platinum-taxane -based chemotherapy and radical surgery.
Abdul Halim, T +14 more
core +1 more source
Drosophila melanogaster as a model for understanding polyADP-ribosylation
Frontiers in Bioscience-Landmark, 2020 PolyADP-ribosylation is a post-translational modification which is involved in various physiological processes including maintenance of genome stability through DNA repair, regulation of transcription, and development.
Masanao Miwa +4 more
doaj +1 more source
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment [PDF]
, 2016 Background: Despite standard treatment for epithelial ovarian cancer (EOC), that involves cytoreductive surgery followed by platinum-based chemotherapy, and initial high response rates to these, up to 80 % of patients experience relapses with a median ...
Caruso, Davide +4 more
core +2 more sources
PARP inhibitors: the race is on [PDF]
British Journal of Cancer, 2016 Since the seminal publications in 2005 that demonstrated the exquisite sensitivity of BRCA1 and BRCA2 (BRCA1/2) mutant cell lines and xenografts to poly(ADP-ribose) polymerase (PARP) inhibition (Bryant et al, 2005; Farmer et al, 2005), the race has been on to exploit single-agent PARP inhibitors for clinical use through the concept of tumour-specific ...
Brown, Jessica S +2 more
openaire +2 more sources
Frontiers in Molecular Biosciences, 2020 The nuclear protein poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors have been proven effective to potentiate both chemotherapeutic agents and radiotherapy.
Ran Wang +9 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Tumors with BRCA1/2 mutations or homologous recombination repair defects are sensitive to PARP inhibitors through the mechanism of synthetic lethality. Several PARP inhibitors are currently approved for ovarian, breast and pancreatic cancer in clinical ...
Xi Zhang +5 more
doaj +1 more source
Dibutyltin(IV) and Tributyltin(IV) Derivatives of meso-Tetra(4-sulfonatophenyl)porphine Inhibit the Growth and the Migration of Human Melanoma Cells [PDF]
, 2019 Melanoma is the most aggressive and deadly form of skin cancer, which is largely due to its propensity to metastasize. Therefore, with the aim to inhibit the growth and the metastatic dissemination of melanoma cells and to provide a novel treatment ...
Caterina Di Sano +5 more
core +3 more sources
Molecular Imaging of PARP [PDF]
Journal of Nuclear Medicine, 2017 The poly(adenosine diphosphate-ribose)polymerase (PARP) family of enzymes is an important factor in the cellular DNA damage response and has gained much attention for its role in many diseases, particularly cancer. Targeted molecular imaging of PARP using fluorescent or radiolabeled tags has followed on the success of therapeutic inhibitors and gained ...
Brandon, Carney +2 more
openaire +2 more sources